IL4 and asthma: PF-07275315 (Tilrekimig) is a trispecific antibody targeting TSLP, IL-4, and IL-13 currently in phase 2 clinical development for the treatment of asthma (NCT06977581) and atopic dermatitis (NCT05995964).